Tadalafil Tablet, Film Coated
Product Images NDC 71205-268

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71205-268). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Tadalafil Figure1)

A set of four line graphs showing blood pressure differences (Tadalafil minus Placebo) over time in hours, for standing systolic and diastolic BP and supine systolic and diastolic BP. Each graph plots the difference in mmHg along the vertical axis against time on the horizontal axis, covering up to 96 hours.*

FDA Label Image

Figure (Tadalafil Figure2)

Two line graphs depicting changes in systolic blood pressure over 24 hours post-dose. The top graph shows standing systolic blood pressure for Tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg. The bottom graph shows supine systolic blood pressure for the same treatments over time.*

FDA Label Image

Figure (Tadalafil Figure3)

A line graph showing the systolic blood pressure (mmHg) changes over 12 hours after administration of tadalafil or placebo, measured at two different times (08:00 and 20:00) alongside 8 mg daily doxazosin. Four different lines represent 20 mg tadalafil at 08:00 and 20:00 and placebo at 08:00 and 20:00, indicating variations in blood pressure response over time.*

FDA Label Image

Figure (Tadalafil Figure4)

A pharmacokinetic line graph showing plasma tadalafil concentration (µg/L) over time (hours) after different dosing regimens: a single 20-mg dose, a single 5-mg dose, and once-daily 5-mg tadalafil after 5 consecutive days. The graph includes error bars representing variability in measurements.*

FDA Label Image

Figure 5 (Tadalafil Figure5)

A line graph comparing change from baseline in IPSS total score over a 12-week treatment duration between tadalafil 5 mg and placebo. The x-axis represents weeks of treatment (0, 4, 8, 12), and the y-axis shows change in score, with both lines showing decreasing scores, tadalafil with a greater reduction than placebo. An asterisk indicates statistical significance (p<0.01) at 12 weeks for tadalafil versus placebo.*

FDA Label Image

Figure 6 (Tadalafil Figure6)

A line graph comparing the change from baseline in IPSS total score over 12 weeks of treatment between tadalafil 5 mg and placebo. The x-axis shows duration of treatment in weeks (0, 1, 4, 8, 12), and the y-axis shows the change from baseline. The tadalafil 5 mg group shows a greater decrease in IPSS score over time than placebo, with statistically significant differences indicated at certain points.*

FDA Label Image

Figure 7 (Tadalafil Figure7)

A line graph depicting least squares mean change from baseline over weeks of therapy for Tadalafil/Finasteride versus Placebo/Finasteride. The x-axis shows weeks (0, 4, 12, 26) and the y-axis shows change from baseline with values decreasing from 0 to -7. Data points for both treatments show downward trends, with statistical annotations for significance levels (p<0.001 and p<0.05) at specific time points.*

FDA Label Image

Figure 8 (Tadalafil Figure8)

A line graph comparing the change from baseline in IPSS total score over a 12-week treatment duration between tadalafil 5 mg and placebo. The graph shows greater reduction in score for tadalafil 5 mg, with marked differences at several time points. The x-axis represents weeks of treatment, and the y-axis represents change from baseline in IPSS score.*

FDA Label Image

71205-268-30 (Tadalafil Label 20mg)

Tadalafil 20 mg film-coated tablets label from Proficient Rx LP. The package contains 10 tablets, each almond-shaped, biconvex, yellow, and debossed with "FJ4" on one side. The label includes NDC 71205-268-10 and manufacturer details for Intas Pharmaceuticals Limited, India.*

FDA Label Image

Chemical Structure (Tadalafil Structure)

Chemical structure of Tadalafil, showing its molecular arrangement with rings and functional groups characteristic of the active ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.